ストックスクリーナーアプリを入手
41.82
0.00%
0.00
アフターアワーズ：
41.82
Immunovant Inc (IMVT) 最新ニュース
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (IMVT) Price Events - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. Q1 2027 Earnings Call Summary - finance.yahoo.com
Immunovant Q1 Earnings Call Highlights - MarketBeat
Form 8K Immunovant Inc For: 6 August By Investing.com - Investing.com Nigeria
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingView
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - The Globe and Mail
Immunovant Fiscal Q1 Loss Widens - marketscreener.com
Immunovant, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss - marketscreener.com
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - theglobeandmail.com
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary - TradingView
Aug 06 (Reuters)Immunovant Q1 Operating Ex - Moomoo
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026 - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - The Manila Times
Immunovant | 8-K: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - Moomoo
IMMUNOVANT Q1 NET INCOME USD -153.224 MILLION VS. IBES ESTIMATE USD -130.2 MILLION - Moomoo
Immunovant earnings up next as analysts eye pipeline pivot - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming DeadlineIMVT; HSACU; HSAC; and HSACW - TMX Newsfile
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00 - GuruFocus
Immunovant (NASDAQ:IMVT) Price Target Raised to $50.00 - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: Navigating a 21.72% Upside Potential in Biotech Investment - DirectorsTalk Interviews
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6. - moomoo.com
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ADAR1 Capital Management LLC Grows Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT - TradingView
Immunovant, Inc. (IMVT) Stock Analysis: Uncovering A Promising 18.57% Potential Upside - DirectorsTalk Interviews
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy - Seeking Alpha
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Immunovant Inc (IMVT) Cash Flow - TradingKey
Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing - marketscreener.com
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMVT|Immunovant Inc|Price:39.410|Chg%:+0.040 - TradingKey
Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com India
Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells $59,699 in shares - Investing.com
Immunovant CFO Tiago Girao sells $263,014 in company stock - Investing.com
Immunovant CTO Jay Stout sells $110,537 in shares - Investing.com
Form 4 Immunovant Inc For: 24 July By Investing.com - Investing.com Nigeria
Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting - Kalkine Media
Immunovant (IMVT) CTO sells 2,857 shares in mandated tax sell-to-cover - Stock Titan
IMVT | Immunovant, Inc. Common Stock Executive Compensation - Quiver Quantitative
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):